共 130 条
[1]
Sarwar N(2010)Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2215-2222
[2]
Gao P(2012)Cardiovascular biology of the incretin system Endocr Rev 33 187-215
[3]
Seshasai SR(2012)The effect of glucagon-like peptide 1 on cardiovascular risk Nat Rev Cardiol 9 209-222
[4]
Gobin R(2004)Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab 287 E1209-E1215
[5]
Kaptoge S(2004)Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 962-965
[6]
Di AE(2006)Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 694-699
[7]
Ingelsson E(2003)Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J Clin Endocrinol Metab 88 220-224
[8]
Lawlor DA(2010)Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes Regul Pept 164 58-64
[9]
Selvin E(2010)Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial Diabet Med 27 1024-1032
[10]
Stampfer M(2008)Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart Regul Pept 146 243-249